Loading…
Tianjin veterinary vaccine maker focused on poultry and livestock biologics for Chinese farms.
Tianjin veterinary vaccine maker focused on poultry and livestock biologics for Chinese farms.
Paid per dose of vaccine, so sales rise and fall with herd sizes and with outbreak pressure that pushes farms to immunise more. Each new vaccine needs its own state veterinary approval, which makes a pipeline of newly cleared products as important as the existing ones.
In one line: A poultry-vaccine Zoetis, China-only.
Moat: narrow (regulatory licence). Licensed veterinary biologics producer within a state-regulated animal-health market.
Headquarters: Tianjin, China · Employees: 2,803
Size Tianjin Ringpu Bio-technology (300119.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 2000th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.27 on 6 Nov 2026.
Performance Over six months the shares fell 4.1%, against -8.1% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 8.7% over the last twelve months (peer median 0.0%); the operating margin is 10.6% (peer median 6.4%).
Valuation It trades at 19.6× forward earnings against a peer median of 19.6× (7th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points above its cost of capital (6.5% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.52B | CN¥3.39B | CN¥3.06B | CN¥2.70B | CN¥2.08B |
| Revenue growth | — | +11% | +13% | +30% | — |
| Gross profit | CN¥1.49B | CN¥1.30B | CN¥1.18B | CN¥1.12B | CN¥956M |
| EBITDA | n/a | CN¥600M | CN¥573M | CN¥517M | CN¥463M |
| Net income | CN¥337M | CN¥401M | CN¥301M | CN¥454M | CN¥347M |
| Free cash flow | CN¥251M | CN¥204M | CN¥588M | CN¥200M | CN¥37.0M |
| Capital expenditure | CN¥267M | CN¥176M | CN¥185M | CN¥252M | CN¥372M |
| Total debt | CN¥1.82B | CN¥1.58B | CN¥1.60B | CN¥1.10B | CN¥986M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Tianjin Ringpu Bio-technology 300119.SZ | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% |
| Jinyu Bio-Technology 600201.SS | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% |
| Pulike Biological Engineering 603566.SS | $475M | -22% | -9% | 5% | 21.0× | 5.7% |
| Zoetis ZTS | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300119.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | -2.2% | 8th highest of 21 |
| 6-month return | -4.1% | -8.1% | 10th highest of 21 |
| Distance from 52-week high | -22.3% | -31.2% | 6th highest of 21 |
| Revenue growth (TTM) | -8.7% | 0.0% | 6th lowest of 19 |
| Operating margin | 10.6% | 6.4% | 10th highest of 20 |
| Forward P/E | 19.6× | 19.6× | 7th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 5.8% | 3.3% | 5th most demanding of 13 |
| Growth delivered (Del g) | +11.3% | +6.1% | 6th highest of 13 |
| Hurdle (Req g minus delivered) | -5.5 pp | -0.4 pp | 5th least demanding of 13 |
| ROIC minus cost of capital | +0.1 pp | -0.2 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |